InflaRx’s (IFRX) Buy Rating Reiterated at HC Wainwright

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $8.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 258.74% from the company’s current price.

InflaRx Stock Performance

Shares of InflaRx stock traded up $0.10 during midday trading on Friday, hitting $2.23. 22,827 shares of the company traded hands, compared to its average volume of 187,848. InflaRx has a 12 month low of $1.16 and a 12 month high of $2.82. The stock has a market cap of $131.31 million, a price-to-earnings ratio of -2.06 and a beta of 1.67. The firm’s fifty day moving average price is $1.92 and its 200-day moving average price is $1.67.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.